M7T mach7 technologies limited

Ann: Change of Director's Interest Notice - ML, page-9

  1. 3,556 Posts.
    lightbulb Created with Sketch. 134
    Agree. A couple of statements didn't add up on the webinars after listening and writing notes on most of them. The mid to high single digit cost growth stated on the webinar blowing out to 19% and 13% the following year was one them. The expectation of two significant contracts to be signed this year only to see PME have blown all the PACS suppliers out of the water with the Trinity Hospital contract. Related - saying that they don't see PME as a competitor. The final straw for me was the Board awarding the LT 200,000 free shares to Mike for EBITDA positive in 2027. The timing of the VA contract as mentioned. The vendor neutral offer is now becoming an issue as the incumbents fight back. Spending a belated paltry $3M to address the issues in their offering does not cut it. Red flag - Ravi announcing his retirement in July from the Singapore office - I should have connected the dots earlier with the major PACS contract win by AGFA in Singapore in July 2024. The lesson is there are many reasons why people retire from companies and it's up to us to dig deeper. I started digging and in 10 seconds found this https://www.agfahealthcare.com/news/agfa-healthcare-signs-key-contract-with-singhealth-for-enterprise-imaging/ Awarded in July .
    Last edited by Ivanovich: 19/12/24
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
42.5¢
Change
0.005(1.19%)
Mkt cap ! $99.86M
Open High Low Value Volume
42.0¢ 42.5¢ 41.0¢ $69.25K 165.1K

Buyers (Bids)

No. Vol. Price($)
1 9066 42.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.0¢ 8319 1
View Market Depth
Last trade - 15.43pm 25/07/2025 (20 minute delay) ?
M7T (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.